Multiple sclerosis: reprogramming the immune repertoire with alemtuzumab in MS.
Results from two phase III trials show the potency of alemtuzumab—a T-cell and B-cell depleting antibody—in reducing clinical and paraclinical measures of disease activity in relapsing–remitting multiple sclerosis. The effects of this immunotherapeutic agent highlight the relevance of T lymphocytes in the early pathogenesis of disease.
Department of Neurology, University of Münster, Albert-Schweitzer-Campus 1, 48129 Münster, Germany. heinz.wiendl@ukmuenster.de
Heinz
H
Wiendl
Bernd
B
Kieseier
D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D015703:Antigens, CD / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D000074301:CD52 Antigen; D017326:Clinical Trials, Phase III as Topic; D006023:Glycoproteins / Q000276:immunology; D006801:Humans; D009103:Multiple Sclerosis / Q000276:immunology* / Q000628:therapy*
D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D006023:Glycoproteins; D000074323:Alemtuzumab